Medicine · Français

Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?

deadline 2027-02-15 confidence medium tier 4 evidence
70%PolySignal estimate

Resolution criterion

Yes if the FDA approves the BLA by 15 February 2027 (Drugs@FDA or a Dyne release). A complete response letter, a postponed PDUFA date, or no decision by that date all count as no.

Verified starting state

BLA accepted for accelerated approval with priority review, PDUFA date 21 January 2027, based on the registrational expansion cohort of DELIVER, with dystrophin production as the primary endpoint. Dystrophin as a surrogate biomarker has been contested since the Sarepta approvals. (20 July 2026)

What pushes it up

What pushes it down

What would move this number most

Whether the FDA accepts the dystrophin biomarker data without issuing a Complete Response Letter or triggering a three-month PDUFA review extension.

How this number is built

Deadline2027-02-15
Base rate73%
Best evidencetier 4 · 2 article(s) used
Independent runs68 · 72 (spread 4 pts)
Confidencemedium
Evidence capnot triggered
Last revised2026-09-21 22:22
Modelgemini-3.6-flash

Sources consulted

Dyne Therapeutics’ z-rostudirsen Wins Priority Review for Duchenne Muscular Dystrophytier 4 · The Clinical Trial Vanguard · 2026-07-21Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)tier 4 · Yahoo Finance · 2026-07-20

Probability history

2026-09-21 22:22 70% 6 article(s) on file · gemini-3.6-flash

Reasons not recorded for this revision (detailed history has only been kept since recently).

2026-09-19 07:40 75% 4 article(s) on file · gemini-3.6-flash

Reasons not recorded for this revision (detailed history has only been kept since recently).